Figures & data
Figure 1 Mechanism of action of T-DM1
Notes: (1) Trastuzumab retains all of its mechanisms of action. It delivers the DM1 chemotherapy directly and specifically to the HER2-positive breast cancer cell. (2) T-DM1 is internalized into the HER2-positive breast cancer cell. (3) DM1 is released once inside the cell. DM1 is a very potent chemotherapy agent that inhibits tubulin development of the mitotic spindle and cell division.
Abbreviations: DM1, emtansine; HER2, human epidermal growth factor receptor 2; T-DM1, trastuzumab emtansine.
Abbreviations: DM1, emtansine; HER2, human epidermal growth factor receptor 2; T-DM1, trastuzumab emtansine.
![Figure 1 Mechanism of action of T-DM1](/cms/asset/f79eb987-2b81-40c7-8066-fc9d7f2e59e6/dbct_a_25114588_f0001_c.jpg)
Table 1 Summary of Phase I clinical trials
Table 2 Summary of Phase II clinical trials
Table 3 Summary of clinical trials currently underway